Press Room

12th DPI China Technology Conference

Start
Thursday, March 27, 2025 - 09:00
End
Friday, March 28, 2025 - 18:00
Location: Nanjing, China
DPI China 2025

Looking for a complete One-Site Solution for your inhalation and nasal therapies? 
Meet Hovione at the 12th DPI China Technology Conference! 

Hovione offers customized high-performance APIs, particle engineering and formulation along with a full range of highly specialized, patented, and innovative devices, all in one site. 

Don’t miss the chance to speak with our Inhalation Experts in Nanjing. Our team is ready to share how this integration on a single site can support your project.

Session Title:
From Particle to Drug Delivery: Integrated Platforms for Respiratory Drug Products
March 28th, 2025
Session III, 11:30 -12:00

Speaker: 
João Pires, PhD - RD Senior Manager, Inhalation and Advanced Drug Delivery at Hovione

Description: This presentation covers the latest trends in pulmonary and nasal formulations and explores how Hovione’s integrated approach addresses the challenges in developing new therapeutics. From innovative formulation and device platforms to a unique set of expertise and capabilities, the session will guide the audience through the drug development cycle of dry powder formulations. It will highlight how an integrated strategy - encompassing formulation, process, and device optimization - can lead to better and more robust respiratory drug products.

Key learnings:

  • Discover the latest advancements in formulation, particle design, and device platforms that address the growing complexity of respiratory formulations and enable next-generation therapeutics
  • Learn how a seamless integration of formulation, process, and device in the drug development cycle can streamline development, reduce risks, and achieve better products

Delivering solutions every breath of the way.

We live and breathe innovation for the successful delivery of your inhalation and nasal therapies.

Schedule a meeting today.

 

 

 

Also in the Press Room

See All

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025